A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Recruiting now · Phase 1
Conditions studied: Carcinoma, Non-small-Cell Lung
In brief
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Key facts
- Study ID
- NCT06116786
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
- People needed
- 126
- Starts
- 2023-11-27
- Expected to finish
- 2029-06-07
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
- Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1 [ROS1], v-raf murine sarcoma viral oncogene homolog B1 [BRAF]) must have received all approved targeted therapies and have progressed
- Part 2: No targetable mutations (for example, EGFR [epidermal growth factor receptor], ALK [anaplastic lymphoma kinase], ROS1[c-ros oncogene 1], and BRAF [B-Raf proto-oncogene, serine/threonine kinase])
- Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
- For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
- For Cohort C of Part 2: Treatment naïve
- Adequate organ function
You may not qualify if…
- Active central nervous system (CNS) disease involvement
- Active autoimmune disease
- Active infection
- History of solid organ or hematologic stem cell transplantation
Where it is running
- City of Hope 1 — Newnan, Georgia, United States (enrolling)
- Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States (enrolling)
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center — New York, New York, United States (enrolling)
- Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
- Next Virginia — Fairfax, Virginia, United States (enrolling)
- Hosp. Univ. I Politecni La Fe — Valencia, Spain (enrolling)
- Universitaetsklinikum Giessen und Marburg GmbH — Giessen, Germany (enrolling)
- Severance Hospital Yonsei University Health System — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Hosp. Univ. Quiron Dexeus — Barcelona, Spain (enrolling)
- Hosp Univ Vall D Hebron — Barcelona, Spain (enrolling)
- Hosp. Univ. 12 de Octubre — Madrid, Spain (enrolling)
- Charite Research Organisation GmbH — Berlin, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.